SEARCH SITE

VIRGINIA LAW PORTAL

SEARCHABLE DATABASES

ACROSS SESSIONS

Developed and maintained by the Division of Legislative Automated Systems.

2015 SESSION

  • | print version

SB 1222 Expanded access to investigational drugs, biological products, and devices.

Introduced by: Bryce E. Reeves | all patrons    ...    notes | add to my profiles

SUMMARY AS INTRODUCED:

Expanded access to investigational drugs, biological products, and devices. Provides that a manufacturer of an investigational drug, biological product, or device may make such investigational drug, biological product, or device available to a person who has a terminal illness when (i) no comparable or satisfactory alternative treatment options approved by the U.S. Food and Drug Administration are available to treat his terminal illness; (ii) the potential benefits of the use of the investigational drug, biological product, or device outweigh the risks of use of the investigational drug, biological product, or device; (iii) his treating physician has recommended use of the investigational drug, biological product, or device; and (iv) the person has provided informed written consent to use of the investigational drug, biological product, or device. The bill provides that a manufacturer that provides an investigational drug, biological product, or device for treatment of a person's terminal illness may provide the investigational drug, biological product, or device free of charge or may require the person to pay costs associated with manufacture of the investigational drug, biological product, or device. The bill also provides that health insurance providers may, but are not required to, provide coverage for costs associated with use of the investigational drug, biological product, or device. This bill was incorporated into SB 732.


FULL TEXT

HISTORY